Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.0B

Nov3Wed

Pre-Earnings Brief

UpcomingQ4-2024After Close5:00 PM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is critical for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine and genetic research continue to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3 2024, Cogent reported an EPS of -$0.64, missing expectations by 17%. The stock reacted with a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the company's recent performance and lack of analyst estimates.

Bull Case

If Cogent can demonstrate improved financial metrics or positive developments in its drug pipeline, it may regain investor confidence and see a stock price increase.

Bear Case

Conversely, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the earnings report fails to meet even lowered expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS figure for Q4-2024?

Given the company's history of missing EPS estimates, this figure will be crucial in assessing financial health and market confidence.

What progress has been made in the drug pipeline?

Investors will be keen to hear about any advancements or setbacks in product development, as this could significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Cogent's drug pipeline to yield positive results, especially given recent advancements in biotechnology.

Supporting Evidence

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent performance trends indicate that even small improvements can lead to significant stock reactions.

Key Risk

If the EPS loss is less than -$0.50, it could shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Cogent can turn around its recent performance or if it will continue to face significant challenges.

Bull Confirmed If

A reduction in EPS loss to -$0.50 or better would confirm a positive shift in financial performance.

Bear Confirmed If

An EPS loss exceeding -$0.70 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around +2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately -3.44%, reinforcing concerns about the company's financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug pipeline and expected timelines for product launches.
2Management's commentary on cost management strategies and their impact on future EPS.
3Insights into market demand for their therapies and any new partnerships.
4Details on research and development expenditures and their expected return.
5Any changes in guidance for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Nov1

AEISReported

Advanced Energy Industries, Inc.

Congress activity

RecapView

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for genetic diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is critical for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q4-2024 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In Q3 2024, Cogent reported an EPS of -$0.64, missing expectations by 17%. The stock reacted with a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the company's recent performance and lack of analyst estimates.

Bull Case

If Cogent can demonstrate improved financial metrics or positive developments in its drug pipeline, it may regain investor confidence and see a stock price increase.

Bear Case

Conversely, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the earnings report fails to meet even lowered expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS figure for Q4-2024?

Given the company's history of missing EPS estimates, this figure will be crucial in assessing financial health and market confidence.

What progress has been made in the drug pipeline?

Investors will be keen to hear about any advancements or setbacks in product development, as this could significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Cogent's drug pipeline to yield positive results, especially given recent advancements in biotechnology.

Supporting Evidence

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent performance trends indicate that even small improvements can lead to significant stock reactions.

Key Risk

If the EPS loss is less than -$0.50, it could shift sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Cogent can turn around its recent performance or if it will continue to face significant challenges.

Bull Confirmed If

A reduction in EPS loss to -$0.50 or better would confirm a positive shift in financial performance.

Bear Confirmed If

An EPS loss exceeding -$0.70 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±10.4%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±10.4% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

34.5%

Calls (74K)P/C Ratio: 0.10Puts (5K)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations, history suggests a potential stock increase of around +2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of approximately -3.44%, reinforcing concerns about the company's financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug pipeline and expected timelines for product launches.
2Management's commentary on cost management strategies and their impact on future EPS.
3Insights into market demand for their therapies and any new partnerships.
4Details on research and development expenditures and their expected return.
5Any changes in guidance for the upcoming quarters.